Cardiac disorders, the “spoilers” of this heart rhythm, may also contain an extremely dangerous “accompaniment” — a blood clot formed — in addition to causing symptoms of discomfort such as panic and heart attack. Anticondensed therapy, like a strong line of defence built on this dangerous edge, is designed to prevent serious cardiovascular events caused by blood bolts and to protect the health of patients with heart disorders.
I. Risk of haemobolism: The “Less” behind the heart disorder
Some cardiac disorders, such as cardiac tremors (house tremors), deprive the heart room of effective condensation, and the blood is bruised in the heart room, as if the water flowed slowly in a narrow and uneven stream and easily formed a blood clot. These embolisms are like a “time-in-time bomb”, which, once removed, flows all over the body with the blood cycle. If it flows to the brain, it can lead to severe consequences, such as paraplegic paralysis, loss of speech and cognitive impairment; if it goes to the coronary artery, it can cause myocardial infarction and severe heart damage; and if it is clogged in the lungs, it can cause pulmonary embolism, causing respiratory difficulties, chest pains and even endangering life. According to statistics, patients with room tremors are 5 – 6 times more at risk than the general population and suffer from severe illness, high disability and high mortality rates. As a result, anticondensation treatment is an urgent matter for patients with heart disorders at risk of haemobolism.
The choice of anticondensed drugs: precision to strike to defuse the blood clot crisis
1. Wafarin: Wafarin is a traditional oral anticondenser that acts as a condenser by inhibiting the synthesis of the coagulation factors on which Vitamin K depends. It’s like setting a level in the “production workshop” of the coagulation factor, which reduces the “material material” formed by the blood clot. However, the use of Wafarin is like a “blade on” and requires close monitoring of the international standardized margin (INR). Because its anticondensation is vulnerable to a number of factors, such as the vitamin K content in the diet (green leaf vegetables are rich in vitamin K), the interaction of medicines, etc. The patient is required to go to the hospital regularly for a blood test INR, which is usually more appropriate to control between 2.0 – 3.0. If INR is too low, the anticondensation effect is inadequate, the risk of embolism increases; if INR is too high, the risk of haemorrhage increases significantly. For example, if a patient who takes Wafalin suddenly increases the intake of green leaf vegetables in his diet without adjusting his dose in time, it may lead to a decrease in INR, rendering anticondensation treatment ineffective.
2. New types of oral anticondensants: With the development of medicine, new types of oral anticondensants, such as Dabiga esters, Lifashaban and Ashaban, have emerged. These drugs have a number of advantages, their resistance to condensation is relatively stable, they are less affected by the interaction between food and drugs, and they do not require routine monitoring of blood condensation indicators, which greatly improves patient accessibility. Darbygar esters are like a “precision shooter”, which directly inhibits the activity of the enzyme and disrupts the critical link of the blood condensed; and Lissal and Arsaban act as a condensor, Xa, as a roadblock on the “highway” of blood condensed to prevent the formation of a leech. However, new oral anticondensants are not perfect, their prices are relatively high, and in some exceptional cases, such as severe kidney failure, they still require careful use and enhanced monitoring.
III. Monitoring and adjustment of anticondensation treatment: dynamic balance to ensure safety and effectiveness
Hemorrhagic risk assessment: Although anticondensed treatment is effective in preventing the formation of a clot, it is a double-edged sword that increases the risk of haemorrhage. As a result, a full risk assessment of haemorrhage is required before and during treatment. The risk of haemorrhage is increased by factors such as older (especially over 75 years of age), combined hypertension, incomplete liver and kidney functioning, previous haemorrhagic history or the use of anti-sphygmoplasia. The doctor weighs the pros and cons of anti-condensation treatment and selects appropriate anti-condensation drugs and doses, depending on the patient ‘ s specific circumstances. For example, when using anticondensatives, a low dose may be selected and monitored for a senior-age, combined with high blood pressure and mild kidney insufficiency.
2. Periodic review and dose adjustment: Both Wafalin and new oral anticondensants require regular hospital review. People who take valarin are subject to frequent monitoring by doctors and to timely adjustment of valorin dosages based on INR results. New oral anticondensants, although they do not require regular monitoring of blood condensation indicators, in exceptional cases, such as when patients experience kidney function changes, significant body weight changes, drug interactions or complications such as haemorrhage, stasis, etc. The doctor, like a “navigator”, constantly adjusts the “direction” to the changes in the patient’s “range” of anticondensation treatment to ensure that the treatment is effective in preventing the haemorrhage and keeping the risk of haemorrhage to a minimum.
IV. Patient self-management: working together to protect the road against condensation
1. Strict compliance with medical instructions: Patients must bear in mind that the use of anticondensed drugs is on time and on a scale, which is key to the success of anticondensed treatment. There must be no self-reducing or arbitrary cuts, which could lead to drastic changes in the risk of haemorrhage or haemorrhage. An alarm or a medical box may be set up to remind itself of the time of taking a drug and to develop a good practice. For example, it is not easy to forget that daily medications are fixed after breakfast.
2. Attention to the interaction between diet and medicine: People who use Wafalin need to pay special attention to vitamin K in their diet and maintain a relatively stable diet. To avoid large-scale consumption of vitamin K-rich foods, such as spinach, broccoli, fragrance, etc., and to pay attention to drugs that may affect the effects of Wafalin, such as antibiotics, antigens and some depressants. Prior to the use of other drugs, doctors should be informed that they are taking anticondensatives in order for doctors to assess the risks of drug interaction and to adjust treatment programmes. While new oral anticondensants are less affected by drug interactions, they are not entirely non-existent and require caution.
3. Vigilance of haemorrhage: During anticondensation treatment, patients must remain vigilant to see if they have haemorrhage. Such as skin bruising, nose bleeding, tooth bleeding, blood urine, black poop, excessive female menstruation, etc. Once these symptoms are detected, they should be immediately referred to the doctor and informed that he is undergoing anticondensation treatment. Depending on the severity of the haemorrhage, doctors take appropriate measures, such as adjusting the dose of anticondensatives, giving stopper drugs or other necessary treatment.
The anticondensive treatment of heart disorders is a fine and long-lasting “war of defense” to find a delicate balance between preventing the formation of blood clots and avoiding the risk of haemorrhage, through the rational choice of anticondensive drugs, close monitoring and adjustment, and active self-management of patients, as well as to carefully calibrate the heart-healthy scales to ensure that people with heart disorders are able to maintain a smooth flow of blood under the escort of the anticondensive treatment, to maintain a smooth and orderly heart rate, to move away from the serious cardiovascular events caused by the blood clots and to move on to a new path to healthy life.
